Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

CD 38 is a multifunctional cell surface protein that has receptor as well as enzyme functions.
The protein is generally expressed at low levels on various hematological and solid tissues …

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or …

Virtually all patients with multiple myeloma become unresponsive to treatment over time.
Relapsed/refractory multiple myeloma (RRMM) is accompanied by the clonal evolution of …

Background Few effective treatments exist for patients with refractory or relapsed and
refractory multiple myeloma not responding to treatment with bortezomib and lenalidomide …

Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical
development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies …

Multiple myeloma (MM), a bone marrow–resident hematological malignancy of plasma cells,
has remained largely incurable despite dramatic improvements in patient outcomes in the …

Control of protein levels by nucleic-acid-based technologies has proven to be a useful
research tool but lacks the advantages of small molecules with respect to cell permeability …

Abstract The Cul4–Rbx1–DDB1–Cereblon E3 ubiquitin ligase complex is the target of
thalidomide, lenalidomide and pomalidomide, therapeutically important drugs for multiple …

Cell surface expression levels of GPRC5D, an orphan G protein–coupled receptor, are
significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or …